The inhibitor has been approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen. OLYSIO works by blocking the viral protease enzyme that enables the hepatitis C virus to replicate in host cells.
More Articles on Supply Chain:
5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics’ Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
